Ocumetics Announces December 20, 2023 Webinar regarding Successful Completion of Animal Study

(TheNewswire)

Ocumetics Technology Corp. (" Ocumetics ") ( TSXV:OTC) (OTC:OTCFF) (FRA:2QBO) a pioneer in the field of ophthalmic innovation, announces a webinar to discuss the successful completion of its biocompatibility animal study and its upcoming first-in-human study, anticipated to commence in Q1 2024 in the Dominican Republic

Dean Burns, CEO of Ocumetics and 27-year Alcon veteran, will lead the presentation.

Click Image To View Full Size

Join the webinar to:

• Learn more about the significance of the biocompatibility animal study;

• Learn more about the upcoming first-in-human study; and

• Ask questions regarding the Ocumetics Accommodating Lens and the company's plans.

Details are as follows:

Date:         December 20, 2023

Time:         18:00 EST

RSVP: https://ocumetics.com/webinar-december-20-2023/

About Ocumetics

Ocumetics Technology Corp. ( TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), headquartered in Calgary, Alberta, Canada, is an innovator in the field of ophthalmic technology, dedicated to developing and commercializing advanced vision correction solutions that enhance the quality of life for individuals worldwide.

Ocumetics is in the preclinical study stage of a game-changing technology for the ophthalmic industry.  In its pursuit of a next generation interocular lens solution, Ocumetics has developed the Ocumetics Accommodating Lens, an expandable intraocular lens that fits within the natural lens compartment of the eye potentially to eliminate the need for corrective lenses.  It is designed to allow the eye's natural muscle activity to seamlessly shift focus from distance to intermediate to near.

FOR FURTHER INFORMATION, PLEASE CONTACT:

Dean Burns
President and CEO
(817) 874-7564

Dayton Marks
Director
(778) 347-2500

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Copyright (c) 2023 TheNewswire - All rights reserved.